One of every 600 black people in the United States has sickle cell anemia. In addition, sickle
cell–hemoglobin C disease and sickle cell–β-thalassemia, which are other common …

Recent molecular studies of fetal hemoglobin (HbF) regulation have reinvigorated the field
and shown promise for the development of clinical HbF inducers to be used in patients with …

A randomized, controlled clinical trial established the efficacy and safety of short‐term use of
hydroxyurea in adult sickle cell anemia. To examine the risks and benefits of long‐term …

The aim of this prospective study was to evaluate the long-term efficacy and safety of
hydroxyurea (HU) in patients with sickle cell disease (SCD). Thirty-four patients with sickle …

In one form of β-thalassemia, a genetic blood disorder, a mutation in intron 2 of the β-globin
gene (IVS2-654) causes aberrant splicing of β-globin pre-mRNA and, consequently, β …

Background: Hydroxyurea is the only approved drug for treatment of sickle cell disease.
Objective: To synthesize the published literature on the efficacy, effectiveness, and toxicity of …

Review Page 1 Review THE ROLE OF HYDROXYUREA IN SICKLE CELL DISEASE
Although the molecular basis for the sickling disorders was identified more than 50 years …

Hydroxyurea (HU) is one of several agents that have been shown to enhance hemoglobin
(Hb) F levels in patients with sickle cell disease and may be useful as a therapy for beta …

The review investigated the evidence surrounding the efficacy, effectiveness and toxicity of
hydroxyurea in the treatment of sickle cell disease. The authors found that hydroxyurea was …

This review addresses several areas of concern in the care of patients with sickle cell
disease. In Sections I and II, the fundamental pathogenetic mechanisms of sickle cell …